Aspen Pharmacare Holdings Ltd

APNJ.J

$11.18

Closing

▼-1.38%

1D

▲5.03%

YTD

Market cap

$4.97B

52 week high

$11.77

52 week low

$8.42

Volume

962,850

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$4.97B

Analysts' Rating

BUY

Price Target (Mean)

0.00

Total Analysts

0

P/E

19.51

Operating Margin

0.00%

Beta

0.85

Revenue Growth (Annual)

-

52 week high

$11.77

52 week low

$8.42

Div. Yield

1.58%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Aspen Pharmacare Holdings Limited is a South Africa-based global specialty and branded multinational pharmaceutical company. The Company focuses on marketing and manufacturing a range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments. Its segments include Manufacturing and Commercial Pharmaceuticals. The Manufacturing segment includes internal and third-party supply of chemical and biochemical active pharmaceutical ingredients (APIs) and finished dose form (FDF) pharmaceuticals. Its Commercial Pharmaceuticals segment comprises Regional Brands and Sterile Focus Brands that include Anaesthetics and Thrombosis products. It operates approximately 23 manufacturing facilities across 15 sites. Its manufacturing capabilities span a variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and APIs. It has a presence in both emerging and developed markets.